Implantica Valuation
Is IMP A SDB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IMP A SDB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IMP A SDB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IMP A SDB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMP A SDB?
Other financial metrics that can be useful for relative valuation.
What is IMP A SDB's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | €670.69m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 415.9x |
Enterprise Value/EBITDA | -27.3x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does IMP A SDB's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 4.5x | ||
SUS Surgical Science Sweden | 1.8x | 22.0% | kr7.9b |
ELOS B Elos Medtech | 7.3x | n/a | kr5.7b |
CEVI CellaVision | 7.2x | 23.6% | kr5.4b |
ARJO B Arjo | 1.6x | 21.1% | kr12.7b |
IMP A SDB Implantica | 5.3x | -3.7% | kr7.8b |
Price-To-Book vs Peers: IMP A SDB is expensive based on its Price-To-Book Ratio (5.3x) compared to the peer average (4.4x).
Price to Earnings Ratio vs Industry
How does IMP A SDB's PE Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Book vs Industry: IMP A SDB is expensive based on its Price-To-Book Ratio (5.3x) compared to the Swedish Medical Equipment industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is IMP A SDB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 5.3x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate IMP A SDB's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.